Objectives: Patients with RA display greater occult coronary atherosclerosis burden and experience higher cardiovascular morbidity and mortality compared with controls. We here explored whether proinflammatory cytokines and high-sensitivity cardiac troponin I (hs-cTnI), a biomarker of myocardial injury, correlated with plaque burden and cardiovascular events (CVEs) in RA.
. High-sensitivity cardiac troponin I correlates with the presence, burden and composition of occult coronary plaque in RA. . High-sensitivity cardiac troponin I further correlates with long-term cardiac events in RA after adjustment for cardiac risk factors. . High-sensitivity cardiac troponin I may serve as a predictive biomarker in refining cardiovascular risk assessment in RA.
Introduction
Individuals with RA experience a higher rate of cardiovascular events (CVEs) compared with controls [1] . This may be explained by the greater prevalence, severity, burden and different composition of occult coronary lesions in RA compared with age-and gender-matched controls [2] . Residual disease activity may further associate with more advanced, complex and prone-to-rupture coronary plaques [2] . Pro-inflammatory cytokines such as TNF-a, IL-6 and IL-17 reflect clinical activity and structural damage in RA and are elevated in the blood of RA patients compared with controls [3] ; the same cytokines have been identified in atherosclerotic plaque [46] and correlated with subclinical atherosclerosis independent of cardiac risk factors [7] , coronary plaque complexity [8] , plaque destabilization and CVEs in subjects without autoimmune disease [911] . Nevertheless, the relationship between these cytokines and occult coronary plaque burden and composition in RA are unknown. Higher plaque load or vulnerability may be further reflected in elevations of biomarkers specific for myocardial injury [12] ; indeed, cardiac troponin elevations measured by high-sensitivity assays-and below thresholds used to diagnose acute coronary syndromes-were associated with higher coronary artery calcium (CAC) scores in a population-based study [12] . Additionally, both high-sensitivity cardiac troponin T (hs-cTnT) and high-sensitivity cardiac troponin I (hs-cTnI) predicted a greater risk of fatal and non-fatal coronary heart disease, heart failure hospitalization and overall mortality in the general population [1215] . In a recent report, hs-cTnI was higher in RA patients compared with controls, independent of cardiovascular risk factors and inflammation [16] . Nevertheless, its association with subclinical coronary artery disease (CAD) burden and its ability to predict future CVEs in RA are unknown. We here hypothesized that hs-cTnI and various pro-inflammatory cytokines may correlate with the presence, burden and composition of occult coronary plaque in patients with RA evaluated with coronary CT angiography (CCTA). We further postulated that hs-cTnI at the time of CCTA might predict incident CVEs on long-term follow-up [60 months (S.D. 26)].
Methods

Patient recruitment
A total of 150 RA patients from a single centre were enrolled and prospectively evaluated on a first-come, first-served basis between 1 March 2010 and 1 March 2011 [2] . The study was approved by the local institutional review board [John F Wolf, MD, Human Subjects Committees (1 + 2)], all subjects signed informed consent and the research was carried out in compliance with the Helsinki Declaration. Inclusion criteria comprised age 518 years, fulfilment of 2010 classification criteria for RA and no symptoms or history of cardiovascular disease, including myocardial infarction (MI), revascularization, heart failure, transient ischaemic attack, stroke or peripheral arterial disease (PAD). Patients with concomitant autoimmune syndromes, malignancy within <5 years, chronic or active infection, weight >325 pounds (147.7 kg), hypotension [systolic blood pressure (SBP) <90 mmHg or diastolic blood pressure (DBP) <60 mmHg] or hypertension (SBP >170 mmHg or DBP >110 mmHg), uncontrolled tachycardia, irregular rhythm, iodine allergy or glomerular filtration rate <60 ml/min were excluded.
Hypertension was defined as SBP 5140 mmHg or DBP 590 mmHg or antihypertensive use. Diabetes mellitus encompassed haemoglobin A1c >6.5% or hypoglycaemic medication use. Hyperlipidaemia constituted fasting cholesterol >200 mg/dl or low-density lipoprotein cholesterol >130 mg/dl or current statin use. Current smoking entailed cigarette consumption within 30 days from screening. Positive family history was defined as CAD in firstdegree relatives <55 years of age for males or <65 years of age for females. The Framingham 2008 D'Agostino modified general cardiovascular risk (FRS-DA) score was calculated for all study participants [17] . Disease duration, serologic status, radiographs and treatments were captured. RA activity was evaluated by a 28-joint DAS with CRP (DAS28-CRP).
Laboratory evaluations
Blood for regular chemistries, fasting lipids, ESR and highsensitivity CRP was collected on the day of CCTA and evaluated at the local laboratory. Additionally, blood was collected in EDTA tubes and immediately processed and plasma was frozen at À80 C until it was assayed. hs-cTnI was measured at Singulex (Alameda, CA, USA) by technicians blinded to the clinical data using a microparticle immunoassay and single-molecule counting [18] . TNF-a, IL-6, IL-17A and F and VEGF were also assessed using laboratory tests developed at Singulex based on singlemolecule counting [18] .
Multidetector CTA Scans were performed with a 64-multidetector row Lightspeed VCT scanner (GE Healthcare, Chicago, IL, USA) between March 2010 and March 2011 and the images were analysed as previously described by a single, blinded interpreter [19] . CAC was quantified by the Agatston method [20] . Coronary arteries were evaluated on contrast-enhanced scans using a standardized 15-segment model [21] . Stenosis severity was scored from 0 to 4 based on the grade of luminal restriction: 1 represented 129% stenosis; 2, 3049%; 3, 5069% and 4, 570%. The area of each plaque visualized in at least two adjacent slices (slice thickness 0.625 mm) was determined on all affected slices. Plaque burden was graded from 0 to 3, defined as none (0), mild (1), moderate (2) and severe (3), based on the number of adjacent slices containing plaque. Lesions rendering >50% stenosis were considered obstructive. Plaque composition was defined as non-calcified, mixed (MP) or calcified (CP), as discussed elsewhere [22] . Subjects received three individual quantitative scores [22] : the segment involvement score (SIS) represented the total number of segments with plaque (015); the stenosis severity score (SSS) reported the cumulative stenosis grade conferred by plaque over all evaluable segments (060) and the plaque burden score (PBS) described the cumulative plaque size over all evaluable segments (045). Reproducibility of scoring measurements for our centre have been previously reported [22] .
Incident CVEs
All patients were followed for incident CVEs over a period of 60 (S.D. 26) months. These included both ischaemic (cardiac death, non-fatal MI, stroke, transient ischaemic attack, PAD) as well as non-ischaemic ones (new-onset heart failure hospitalization). Event adjudication was elaborated by the treating cardiologist, neurologist or vascular surgeon and based on standard definitions [2325] .
Analysis
Continuous variables are expressed as medians with interquartile ranges (IQRs) and categorical variables are expressed as numbers with percentages. Spearman's rho correlation coefficients evaluated preliminary associations between biomarkers and plaque outcomes. Medians between CVE groups were compared using the MannWhitney U test and counts by the chi-square test. Further analyses were restricted to biomarkers with significant differences. Plaque outcomes were binarized based on median; those were >0 vs 0 for CAC, >1 vs 41 for SIS, >1 vs 41 for SSS and >2 vs 42 for PBS. To evaluate plaque composition, the presence of MP or CP vs the absence of both was used as an outcome. Similarly, hs-cTnI was binarized as high (>1.5 pg/ml) vs low (41.5 pg/ml). Logistic regression models were constructed to evaluate associations between hs-cTnI and individual plaque parameters; models were adjusted for either age and gender (model 1) or additionally for hypertension, diabetes, hyperlipidaemia, smoking, BMI and prednisone use (model 2) or for the patients' FRS-DA score (model 3). Similar logistic regression models were devised to predict individual or composite high-risk plaque outcomes; individual ones included CAC >100 vs 4100, SIS >5 vs 45, SSS >5 vs 45 and the presence of obstructive plaque vs not. Composite outcomes entailed the presence of SSS >5 or CAC >100 vs neither and SIS >5 or SSS >5 or obstructive plaque vs none. Results are reported as odds ratios with 95% CIs.
For composite and plaque composition outcomes, sensitivity, specificity and negative and positive predictive values were determined with standard formulas. Cox proportional hazards regression analysis evaluated CVE risk [hazard ratio (HR)] associated with high cTnI (>1.5 pg/ml) in raw and several adjusted models (models 1, 2 and 3) as previously described. KaplanMeier curves were compared by the log-rank method. The diagnostic accuracy of CVE risk assessment for FRS-DA alone, FRS-DA + hscTnI, and FRS-DA + hs-cTnI + high-risk composite outcome was evaluated as the area under the receiver operator characteristic curve and compared with the DeLong method. Integrated discrimination improvement (IDI) between these constructs was computed and improvement in prediction accuracy was evaluated, where P-values <0.05 were significant. Data were analysed with SAS version 9.4 (SAS Institute, Cary, NC, USA) or R version 3.4.1 (R Project for Statistical Computing, Vienna, Austria).
Results
Patient demographics are shown in Table 1 . Subjects were predominantly female, with established seropositive, erosive and well-controlled disease. RA parameters and traditional cardiac risk factors were not significantly different in patients incurring CVEs. In contrast, FRS-DA, coronary atherosclerosis burden, including high-risk plaque parameters, and levels of hs-cTnI were significantly higher (all P < 0.05).
Correlations of cytokines and hs-cTnI with occult coronary atherosclerosis TNF-a, IL-6, IL-17A, IL-17F and VEGF showed no correlations with any coronary plaque parameters or hs-cTnI (supplementary Table S1 , available at Rheumatology online) and neither did ESR, CRP, tender joint count, swollen joint count or DAS28-CRP (data not shown). hs-cTnI was detectable in all patients [1.5 (IQR 1.12.6) pg/ml]; patients with any plaque had higher levels compared to those without [1.8 (IQR 1.12.6) pg/ml vs 1.3 (0.91.8); P = 0.02]. Moreover, hs-cTnI was correlated with all occult coronary plaque outcomes (all P < 0.01). CAC, SIS, SSS and PBS substantially increased from the lowest to the highest hs-cTnI tertile (P for trend = 0.006, 0.005, 0.01 and 0.009, respectively). Similarly, high-risk plaque outcomes such as CAC >100, SIS >5, SSS >5, obstructive plaque, composite outcome and presence of any advanced MP/CP lesions were considerably enriched across higher hs-cTnI tertiles (Fig. 1). hs-cTnI independently correlates with plaque burden and composition hs-cTnI levels associated with all plaque outcomes ( Table 2) . After controlling for age and gender (model 1), additional adjustments for hypertension, diabetes, hyperlipidaemia, smoking, BMI and prednisone use (model 2) or FRS-DA score (model 3), hs-cTnI remained predictive of CAC, SSS and PBS. Furthermore, it associated with the presence of more advanced mixed or calcified plaques but showed no correlation with earlier, non-calcified lesions. Importantly, hs-cTnI further correlated with highrisk outcomes such as obstructive plaque, SSS >5, CAC 5100 or composite endpoints (Table 2) ; significance persisted for several, even after adjustments for cardiac risk factors or FRS-DA scores.
Conversely, subjects with low hs-cTnI (<1.5 pg/ml) were less likely to have extensive coronary atherosclerosis. Specifically, they displayed 81% lower risk of having SSS >5 or CAC 5100 and 70% less risk of obstructive plaque, SIS >5 or SSS >5 after controlling for FRS-DA score; the area under the curve (AUC) improved from 0.79 (IQR 0.630.95) to 0.85 (0.720.98), P < 0.05 (data not shown). Out of all patients, 27 (18%) had CAC >100 or SSS >5 and 22 (15%) had obstructive plaque or SIS >5 or SSS >5. Compared with all patients, only 8% with low hs-cTnI displayed those respective plaque outcomes (supplementary Table S2 , available at Rheumatology online); of patients with both low hs-cTnI and low FRS-DA scores, only 4% had extensive atherosclerosis compared with 11% of those with just low FRS-DA.
Elevated hs-cTnI associates with long-term CVEs in RA Eleven patients suffered CVEs during 60 (S.D. 26) months of follow-up (1.54/100 patient-years): eight were ischaemic, including one cardiac death, three non-ST elevation MIs, two strokes and two PAD events requiring revascularization; the three non-ischaemic events were newonset hospitalized heart failure. hs-cTnI was higher in patients with CVEs vs those without [2.6 pg/ml (IQR 2.14.4) vs 1.5 (1.02.4), P = 0.006]. Elevated hs-cTnI predicted the risk of incident CVEs ( Fig. 2A , P = 0.03), independent of demographics and traditional cardiac risk factors (Table  3) . Importantly, patients with low hs-cTnI were 82% less likely to suffer a CVE.
hs-cTnI enhances CVE risk prediction when added to cardiac risk scores
The prognostic accuracy of FRS-DA alone vs FRS-DA + hs-cTnI and FRS-DA + hs-cTnI + high-risk plaque for CVEs based on the AUC of the respective receiver operating characteristics curves is depicted in Fig. 2B . The addition of hs-cTnI information to the FRS-DA score yielded a higher prognostic accuracy (0.8431 vs 0.7283; P = 0.10); further addition of high-risk plaque information from CCTA (obstructive plaque or SIS >5 or SSS >5) resulted in significant enhancement of the predictive accuracy over the FRS-DA alone (0.9165 vs 0.7283; P = 0.015) and an improving trend over the FRS-DA + hscTnI (0.9165 vs 0.8431; P = 0.21). Since the AUC change in Current smoker, n (%) 13 (9) 12 (9) 1 (9) Family history of CAD, n (%) 6 (4) 5 (3.6) 1 (9) Hyperlipidaemia, n (%)
26 (17) 25 (18) All stages of the atherogenic process appear enhanced in RA, including endothelial dysfunction, increased arterial stiffness, plaque formation and finally CVEs [30] . Distinct biomarkers may reflect different stages of this pathway, from inflammation (high-sensitivity CRP, IL-6) to plaque instability (myeloperoxidase, MMPs), thrombosis (fibrinogen), myocardial stress (NT-proBNP) and myocardial necrosis (hs-cTn). Individual associations of CRP, hscTn and NT-proBNP with CVE in general patients have been extensively described [31] . In RA, CRP may reflect uncontrolled systemic inflammation rather than being a surrogate for the extent of vascular involvement [30] . NT-proBNP independently predicted mortality in one study of 182 RA patients [32] .
Our study shows for the first time that hs-cTnI, a specific structural myocardial biomarker, may optimize long-term cardiovascular risk prediction in RA. Blood concentrations of cardiac troponin I and T subunits are elevated in the context of myocardial injury [33] . High-sensitivity assays measure cTnI concentrations at levels much lower than conventional assays with excellent precision at a 410% coefficient of variation, both at and below the assay's 99th percentile value. This added sensitivity allows reliable estimation in almost 100% of healthy individuals and identification of subclinical myocardial injury [34] . Elevated hs-cTnI was associated with incident long-term CVEs in patients with RA when controlling for traditional cardiac risk factors. This is consistent with reports in population-based studies that subthreshold elevations of either hs-cTnT or hs-cTnI predicted a higher risk of CVEs, heart failure hospitalization and mortality [1215] . In contrast, RA patients with low hs-cTnI were 82% less likely to suffer a CVE. This approximates the estimated 88% lower risk of CV death in a nested casecontrol study in general patients with low hs-cTnI measured with the same assay [35] . Moreover, we demonstrated that hs-cTnI measurements significantly improved discrimination of long-term incident CVE risk over composite cardiac risk scores alone. A combination of CRP, NT-proBNP and hs-cTnI optimized the 10-year CVE risk prediction in two general European populations [36] ; however, these have not yet been evaluated in RA. In our study, IL-6 was numerically higher in patients incurring CVEs. Nevertheless, a model of high IL-6 combined with hs-cTnI did not optimize event prediction over hs-cTnI alone (data not shown). More multibiomarker groupings will likely emerge in the future. However, the optimal prognostic combinations remain to be defined.
Our second novel finding was the association of hs-cTnI with coronary plaque presence, burden and composition in patients with RA, as measured by CCTA. This non-invasive imaging modality has significantly enhanced the prediction of incident CVEs beyond clinical risk scores, as well as CAC in general patients without known CVD [37, 38] . In a prospective study, 69% of subjects with obstructive lesions suffered events at 52 months compared with 28% of those with non-obstructive lesions and 0% of those without plaque. Similarly, 75% with SIS >5 and 80% with SSS >5 suffered CVEs compared with 23% with SIS 45 and 15% with SSS 45 [39] . hs-cTnI was considerably higher in patients with any plaque vs those without; furthermore, it significantly increased across higher plaque burden scores. This is consistent with a prior report in general patients showing progressively higher hs-cTnT in those with mild, moderate and multivessel CAD on CCTA [40] . hs-cTnI was strongly correlated with all quantitative plaque outcomes, including several high-risk ones (obstructive plaque, SSS >5, CAC >100 and composites thereof) after adjustments for traditional   FIG. 1 Several high-risk coronary plaque burden outcomes are significantly enriched across higher tertiles of hs-cTnI hs-cTnI tertile ranges were 41.2, 1.22.1 and 52.1 pg/ml. P-values for trend determined by the Jonckheere Terpstra test.
y P < 0.1, *P < 0.05, **P < 0.01, ***P < 0.001.
risk factors and cardiovascular scores. Moreover, it independently predicted the presence of any advanced-mixed or calcified-coronary plaque, whereas it showed no correlation with earlier non-calcified plaques. In our study, hs-cTnI significantly improved the discrimination of long-term incident CVE risk over cardiac risk scores alone. Additional information on the presence of high-risk plaque outcomes from CCTA further optimized CVE risk discrimination compared with cardiac risk scores and hs-cTnI together. These observations provide the theoretical framework and a testable hypothesis for a twostep algorithm to optimize CVE risk prediction in RA. As part of the cardiac risk stratification, physicians could measure plasma hs-cTnI. If high (>1.5 pg/ml), it may foreshadow a significant hazard for high-risk plaque burden, vulnerability or future CVEs above and beyond cardiac risk scores. In that context, further non-invasive evaluation of coronary atherosclerosis with CCTA may refine primary prevention recommendations based on the presence and burden of coronary plaque. In contrast, if hs-cTnI is low (41.5 pg/ml), the risk of significant coronary atherosclerosis and CVE is substantially decreased. Therefore physicians may narrow their recommendations to address potential actionable clinical risk factors in accordance with cardiac scores.
In our study, hs-cTnI was measured at the time of CCTA, when no chest pain was present. In fact, by design, enrolees had no symptoms or diagnosis of CVD upon study entry, hence elevated hs-cTnI levels likely reflect latent myocyte damage. Higher hs-cTnI in general patients has been associated with unstable plaque features on CCTA [41] , reflecting intermittent, chronic and clinically silent plaque remodelling and/or rupture with subsequent microembolization, leading to unrecognized MIs (UMIs) [42, 43] . Consistent with these reports, we showed that hs-cTnI in RA patients only correlated with higher-complexity mixed or calcified plaques, independent of cardiac risk factors or Framingham scores but not earlier non-calcified lesions. Greater hs-cTnI associated with the presence of UMIs at baseline, as well as with new or larger UMIs on MRI 5 years later, in a series of community-living volunteers without a history of MI [44] . RA patients are far more likely to experience UMIs, even prior to their RA diagnosis [45] . Indeed, in a pilot MRI study, 39% of RA patients without symptomatic CVD had delayed enhancement suggesting myocardial inflammation or scarring and 11% had nodular subendocardial delayed enhancement indicating silent MI [46] . Latent troponin leak has further been reported as a result of impaired cell membrane integrity due to systemic inflammation [47] . However, we observed no associations between hs-cTnI, inflammatory markers or cytokines, making inflammation an unlikely driver, consistent with an earlier report [16] .
Interestingly, we observed no association between proinflammatory cytokines, ESR or CRP and the burden of coronary atherosclerosis. This observation may be partially explained by the fact that 58% of our patients were in remission (DAS28-CRP <2.6) at the time of CCTA, while 75% overall had low disease activity (DAS28-CRP <3.2) and 60% were under chronic anti-TNF medication exposure. Concordantly, in the vast majority, IL-6, IL-17A and IL-17F levels were well below the 99% threshold observed in normal patients and similar to or lower than those reported by studies in treated RA patients using identical measurement assays [48, 49] .
Our study has certain limitations. Causal relationships between hs-cTnI levels and plaque burden or composition may not be inferred due to their cross-sectional evaluation. Moreover, since our patients were well controlled and the levels of pro-inflammatory cytokines studied were generally low and reflective of that state, we may have underestimated the association of inflammation with both hs-cTnI and plaque burden. Our broader study design, of which the current report is a part, was powered to evaluate quantitative and qualitative plaque differences between 150 RA patients and an equal number of ageand gender-matched patients without autoimmune disease. Although evaluations of biomarkers and their associations with plaque presence, burden and composition in RA patients were pre-specified as exploratory analyses, they were not specifically powered for. Our findings would therefore have to be tested in larger, specifically powered studies and our proposed two-step algorithm for optimization of CVE risk prediction prospectively validated within that context. CVEs appear numerically low in our study [11 patients (6. 1%)], which may have deflated overall significance rates-despite sizeable area differences-in AUC curves between FRS-DA alone and FRS-DA + hs-cTnI as well as between FRS-DA + hs-cTnI and FRS-DA + hs-cTnI + high-risk CCTA. This was certainly contributed to by our study design, which pre-specified recruitment of subjects without symptoms or prior diagnosis of CVD. Despite this, our observed event rate was 1.5/100 patient-years, which is similar to studies specifically designed for CV risk [50] , and is considered high overall for populations of well-controlled patients chronically exposed to biologic agents.
In conclusion, we show for the first time that hs-cTnI associates with the presence, burden and composition of coronary artery atherosclerosis in RA patients without symptoms or prior diagnosis of cardiovascular disease above and beyond traditional risk factors, cardiovascular scores or inflammation. hs-cTnI further associates with the long-term risk of incident CVEs beyond demographics and traditional cardiac risk factors and improves discrimination for such risk prediction beyond that rendered by cardiac risk scores. It may provide a mechanistic explanation for the greater morbidity and mortality RA patients incur and may serve as an adjunct predictive biomarker in refining cardiovascular risk determination in RA.
Supplementary data
Supplementary data are available at Rheumatology online. 
